Q1 EPS Estimates for Henry Schein Reduced by William Blair

Henry Schein, Inc. (NASDAQ:HSIC) – Analysts at William Blair dropped their Q1 2025 EPS estimates for Henry Schein in a research report issued to clients and investors on Tuesday, March 11th. William Blair analyst B. Vazquez now forecasts that the company will post earnings per share of $1.10 for the quarter, down from their prior estimate of $1.16. The consensus estimate for Henry Schein’s current full-year earnings is $4.74 per share. William Blair also issued estimates for Henry Schein’s Q2 2025 earnings at $1.17 EPS, Q3 2025 earnings at $1.35 EPS, Q4 2025 earnings at $1.25 EPS, FY2025 earnings at $4.87 EPS, Q1 2026 earnings at $1.17 EPS, Q2 2026 earnings at $1.23 EPS, Q4 2026 earnings at $1.35 EPS and FY2026 earnings at $5.17 EPS.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $1.19 earnings per share for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.04). The firm had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.25 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.66 earnings per share.

A number of other equities analysts have also recently weighed in on the stock. Barrington Research reissued an “outperform” rating and set a $90.00 price target on shares of Henry Schein in a research report on Wednesday, February 26th. Mizuho started coverage on shares of Henry Schein in a report on Wednesday, December 4th. They set a “neutral” rating and a $75.00 price objective on the stock. UBS Group dropped their price objective on shares of Henry Schein from $83.00 to $80.00 and set a “neutral” rating on the stock in a report on Wednesday, February 26th. Bank of America upgraded shares of Henry Schein from an “underperform” rating to a “buy” rating and raised their price objective for the stock from $69.00 to $84.00 in a report on Monday, January 6th. Finally, Jefferies Financial Group raised their price objective on shares of Henry Schein from $77.00 to $80.00 and gave the stock a “hold” rating in a report on Thursday, January 23rd. Six research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $81.10.

Henry Schein Trading Down 4.1 %

Shares of NASDAQ HSIC opened at $69.94 on Thursday. The company’s fifty day moving average is $74.77 and its 200-day moving average is $72.64. The stock has a market cap of $8.68 billion, a price-to-earnings ratio of 28.78, a P/E/G ratio of 2.13 and a beta of 0.90. Henry Schein has a twelve month low of $63.67 and a twelve month high of $82.49. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46.

Institutional Trading of Henry Schein

Several hedge funds and other institutional investors have recently modified their holdings of HSIC. Palestra Capital Management LLC bought a new stake in shares of Henry Schein during the 4th quarter worth about $182,988,000. Lyrical Asset Management LP bought a new stake in Henry Schein in the 4th quarter valued at about $126,655,000. Norges Bank bought a new stake in Henry Schein in the 4th quarter valued at about $103,301,000. Steadfast Capital Management LP boosted its holdings in Henry Schein by 254.2% in the 4th quarter. Steadfast Capital Management LP now owns 1,637,808 shares of the company’s stock valued at $113,336,000 after purchasing an additional 1,175,408 shares during the period. Finally, ING Groep NV bought a new stake in Henry Schein in the 3rd quarter valued at about $63,226,000. Institutional investors own 96.62% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.